Kirk Nielsen is a Managing Director at Versant Ventures. Kirk joined Versant from Medtronic, where he worked in sales & marketing in the company’s Cardiac Rhythm Management division. Previously, he spent time at Fluidigm (a Versant portfolio company) and he also served as a consultant at Bain & Company, where he advised clients in healthcare, private equity, and other industries. Prior to his business career, Kirk was a professional hockey player. At Versant, Kirk has led or co-led investments in Biotie (IPO/sale announced), CardiAQ (sold), Cameron Health (sold), Lutonix (sold), Holaira, Inari Medical, Metavention, NeuWave Medical, Respicardia, Sequent Medical, Veran Medical, and Zyga Technology. Based in Minneapolis, he also leads the firm’s activities in the Midwest. Kirk earned a biology degree with honors from Harvard College, where he won the John P. Reardon, Jr. award as the school’s most outstanding scholar-athlete, and an MBA from Harvard Business School, where he was a Baker Scholar.